Clinical Report: Uncommon Factor V Inhibitor in Ulcerative Colitis Patient

Overview

This report details a case of acquired factor V deficiency (AFVD) in a patient with ulcerative colitis and latent tuberculosis infection. The patient's condition improved significantly following the administration of immunomodulatory treatment and preventive anti-tuberculosis therapy.

Background

Acquired factor V deficiency is a rare condition that can lead to severe bleeding due to the presence of FV inhibitors. Diagnosing AFVD can be particularly challenging, especially in patients with concurrent conditions such as ulcerative colitis and latent tuberculosis infection. Understanding the interactions between these diseases and their treatments is crucial for effective management.

Data Highlights

No numerical data or trial data is provided in the article.

Key Findings

• Acquired factor V deficiency can occur in patients with ulcerative colitis and latent tuberculosis infection.
• High-titer FV inhibitors were detected in the patient, complicating the clinical picture.
• Traditional treatments targeting the primary disease did not improve the patient's condition.
• Immunomodulatory treatment with intravenous immunoglobulin led to the elimination of FV inhibitors.
• Preventive anti-tuberculosis therapy contributed to significant improvement in the patient's symptoms.

Clinical Implications

Healthcare professionals should consider the possibility of acquired factor V deficiency in patients with ulcerative colitis, especially those with latent tuberculosis infection. Early detection and appropriate immunomodulatory treatment may be necessary to manage this rare condition effectively.

Conclusion

This case highlights the importance of recognizing and treating acquired factor V deficiency in patients with complex medical histories, leading to improved clinical outcomes.

Related Resources & Content

1. Journal of Crohn's and Colitis, 2023 -- Uncovering the therapeutic potential of anti-tuberculoid agent Isoniazid in a model of microbial-driven Crohn’s disease
2. Infection, 2023 -- Diagnosis of Disseminated Tuberculosis via Positron Emission Tomography and Mini-Laparoscopy in a Patient Undergoing TNF-α Inhibitor Treatment
3. Open Forum Infectious Diseases, 2023 -- Challenges Associated with the MTB/RIF Assay: A Review of Four Clinical Cases
4. Laboratory investigation and clinical management of acquired coagulation factor inhibitors: A joint British Society for Haematology and United Kingdom Haemophilia Centre Doctors' Organisation Guideline - PubMed
5. Acquired factor V inhibitor: a nation‐wide study of 38 patients
6. Clinical Rheumatology — Exploring the Relationship Between Systemic Vasculitis and Latent Tuberculosis Infection: Findings from a Multicenter Cross-Sectional Study
7. Latent Tuberculosis Infection Testing and Treatment: Summary of U.S. Recommendations | Tuberculosis (TB) | CDC
8. New ECCO Guidelines on Opportunistic Infections in IBD – 2025 Update - ECCO - European Crohn’s and Colitis Organisation
9. Laboratory investigation and clinical management of acquired coagulation factor inhibitors: A joint British Society for Haematology and United Kingdom Haemophilia Centre Doctors' Organisation Guideline - PubMed
10. Acquired factor V inhibitor: a nation‐wide study of 38 patients
11. Acquired factor V inhibitor masked by triple antithrombotic therapy presenting as severe gastrointestinal bleeding: a case report | Thrombosis Journal | Springer Nature Link
12. 086250: Factor V Activity With Inhibitor Reflex | Labcorp
13. Frontiers | Case Report: Rare Factor V Inhibitor Found in a Patient with Ulcerative Colitis During Latent Tuberculosis Infection
14. Déficit acquis en facteur V: A propos d'un cas - ProQuest
15. Coagulation factor V inhibitors, a review of the case report literature - ScienceDirect